GC
BCRX icon

Grimes & Company’s BioCryst Pharmaceuticals BCRX Stock Holding History

Grimes & Company’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$469K Buy
46,850
+8,898
+23% +$80.5K 0.01% 319
2026
Q1 		$361K Hold
37,952
– – 0.01% 338
2025
Q4 		$296K Sell
37,952
-16,011
-30% -$116K 0.01% 385
2025
Q3 		$410K Buy
53,963
+489
+0.9% +$4.07K 0.01% 331
2025
Q2 		$479K Sell
53,474
-19,233
-26% -$179K 0.01% 272
2025
Q1 		$545K Sell
72,707
-2,568
-3% -$20.7K 0.02% 232
2024
Q4 		$566K Hold
75,275
– – 0.02% 239
2024
Q3 		$572K Hold
75,275
– – 0.02% 223
2024
Q2 		$465K Buy
75,275
+3,836
+5% +$21.2K 0.01% 227
2024
Q1 		$363K Sell
71,439
-916
-1% -$5.15K 0.01% 251
2023
Q4 		$433K Sell
72,355
-1,220
-2% -$7.07K 0.01% 232
2023
Q3 		$521K Buy
73,575
+903
+1% +$6.49K 0.02% 204
2023
Q2 		$512K Buy
72,672
+350
+0.5% +$2.81K 0.02% 205
2023
Q1 		$603K Buy
72,322
+415
+0.6% +$4K 0.02% 184
2022
Q4 		$825K Sell
71,907
-40
-0.1% -$499 0.03% 171
2022
Q3 		$907K Buy
71,947
+948
+1% +$12.2K 0.05% 149
2022
Q2 		$751K Buy
70,999
+2,238
+3% +$23.1K 0.04% 162
2022
Q1 		$1.12M Buy
68,761
+3,289
+5% +$52.8K 0.06% 151
2021
Q4 		$907K Buy
65,472
+12,801
+24% +$169K 0.04% 169
2021
Q3 		$757K Buy
52,671
+2,066
+4% +$32.6K 0.03% 176
2021
Q2 		$800K Sell
50,605
-1,157
-2% -$15.7K 0.03% 169
2021
Q1 		$526K Buy
51,762
+15,812
+44% +$163K 0.03% 187
2020
Q4 		$268K Buy
35,950
+20,950
+140% +$108K 0.01% 229
2020
Q3 		$52K Buy
+15,000
New +$64.3K ﹤0.01% 246

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Grimes & Company's BCRX Position: Q2 2026 in Review

Grimes & Company increased its BioCryst Pharmaceuticals (BCRX) stake by 23% in Q2 2026, buying an estimated $80.5K and bringing the position to 46,850 shares worth $469K. The position accounts for 0.01% of the portfolio, ranked #319.

Grimes & Company first reported a position in BCRX in Q3 2020 and has held it in 24 quarters since. The position peaked at $1.12M in Q1 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Grimes & Company held 46,850 shares of BioCryst Pharmaceuticals worth $469K as of Q2 2026.
  • Grimes & Company bought 8,898 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $80.5K.
  • BioCryst Pharmaceuticals made up 0.01% of Grimes & Company's portfolio in Q2 2026, its #319 holding.
  • Grimes & Company first reported a position in BioCryst Pharmaceuticals in Q3 2020 and has held it in 24 quarters since.
  • Grimes & Company's BioCryst Pharmaceuticals position peaked at $1.12M in Q1 2022.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.